Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Battle For Power At Actelion, Major Shareholder Supports Incumbent Management

This article was originally published in The Pink Sheet Daily

Executive Summary

BB Biotech's support is critical for Actelion to fend off activist shareholder's moves to force a sale of the group.

You may also be interested in...

Switzerland's Actelion Calls In Garnier And Bertolini To Bolster Board

Two industry heavyweights nominated to Actelion's board of directors, but analysts skeptical that changes will quickly follow.

Actelion Punches Back Against Activist Shareholder

Actelion's board vice-chairman Joe Scodari highlights 'fallacies' in activist shareholder's call for sale.

Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada

A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts